trial

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCTId NCT00218218
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 48 (actual)
Sponsored by National Institute on Drug Abuse (NIDA)
Primary completion 2005-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2002-06
Primary completion
2005-02
Eligibility
ALL · 18 Years · 80 Years

Interventions & indications

Drugs
Transdermal nicotine patch21 mg transdermal nicotine

Sponsors

National Institute on Drug Abuse (NIDA)Lead Sponsor

Investigators

1
Jennifer Tidey, PhDPrincipal Investigator

Sites

2 total
Providence, United StatesProvidence, United States

Linked catalysts

1
Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People Wit — primary completion2005-02

Facts & assertions

4 sourced
Enrollment
48
Phase
PHASE2
Primary Completion Date
2005-02
Status
COMPLETED
relationships
The graph out of here
drug
Transdermal nicotine patch
drug
21 mg transdermal nicotine
drug
lead_sponsor
National Institute on Drug Abuse (NIDA)
company
indication
Tobacco Use Disorder
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication
investigator
Jennifer Tidey, PhD
person